Dualitas Therapeutics Appoints Karim Dabbagh as Chief Executive Officer to Advance Novel Bispecific Antibody Pipeline Toward the Clinic
* Karim Dabbagh, Ph.D., joins as CEO, bringing leadership experience in advancing immunology and inflammation therapies through clinical trials; Rich Murray, Ph.D., former interim CEO, remains on the Board of Directors
* Dualitas announces the nomination of DTX-102 as its lead development candidate, a bispecific antibody powered by a